Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alkermes Plc
(NQ:
ALKS
)
24.15
-0.31 (-1.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
Next >
Earnings Preview: Alkermes
July 26, 2022
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...
Via
Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
Northrop Grumman Leads 5 Defensive Plays Near Buy Points
July 02, 2022
Northrop headlines 5 stocks near buy points with the mettle to withstand a recession.
Via
Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
June 15, 2022
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92.
Via
Investor's Business Daily
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
June 11, 2022
New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for...
Via
Talk Markets
Recap: Alkermes Q1 Earnings
April 27, 2022
Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings for Alkermes
April 21, 2022
Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
June 05, 2022
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Via
Benzinga
Best Stocks To Buy Now: June 02, 2022
June 02, 2022
The stock market continues to be one of the best ways for regular investors to build wealth over time. The
Via
Best Stocks
Topics
Artificial Intelligence
Cannabis
Exposures
Artificial Intelligence
Cannabis
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
May 22, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...
Via
Talk Markets
Looking Into Alkermes's Return On Capital Employed
April 28, 2022
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.
Via
Benzinga
61 Biggest Movers From Yesterday
April 28, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...
Via
Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
April 27, 2022
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of...
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Alkermes's Earnings Outlook
April 26, 2022
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 22, 2022
Alkermes (NASDAQ:ALKS) will host a conference call at 08:00 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Alkermes (ALKS) Conference Call Follow this link to access the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022
April 20, 2022
Upgrades
Via
Benzinga
Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen
April 19, 2022
Via
Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
March 31, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,...
Via
Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
March 24, 2022
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
March 14, 2022
Sentiment was low heading into the study and analysts aren't hopeful for other tests.
Via
Investor's Business Daily
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
February 17, 2022
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant...
Via
Benzinga
Alkermes's Return On Capital Employed Overview
February 17, 2022
According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31%...
Via
Benzinga
56 Biggest Movers From Yesterday
February 17, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead...
Via
Benzinga
Why Are Alkermes Shares Trading Higher Today?
February 16, 2022
Alkermes plc's (NASDAQ: ALKS) Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million. Net sales of proprietary products were $178.9...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
February 16, 2022
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.